Remote monitoring of blood pressure in women who have just given birth using a smartphone app can eliminate a disparity in care between Black and White patients, according
Just weeks after wagering $310 million upfront on the rights to Alnylam's hypertension therapy zilebesiran on the strength of phase 1 data, Roche has been rewarded by a po
Idorsia has lost Johnson & Johnson's Janssen Biotech unit as the partner for its aprocitentan candidate for resistant hypertension, following a likely delay in the FDA
Roche has paid $310 million upfront for rights to Alnylam Pharma's zilebesiran for hypertension, a handsome sum for a drug that so far has only generated phase 1 data.
In this episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Marc de Garidel, CEO of CinCor Pharma, which was just recently sold to AstraZeneca for more than $1 bill
Eisai and Biogen have their second regulatory approval for anti-amyloid therapy Leqembi – in Japan – as a treatment for slowing the progression of Alzheimer’s disease.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho